The American Journal of Managed Care11 天
5 Potential Therapeutic Targets for Small Cell Lung Cancer
According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune ...
John B. Amos among first to give new cancer treatment in Georgia
Columbus’ John B Amos Cancer Center is now leading the way to administer a new cancer treatment in the Peach State.The ...
The American Journal of Managed Care12 天
Small Cell Lung Cancer
Heather Wakelee, MD, Stanford University, discusses the pros and cons of different durations of immunotherapy in non-small cell lung cancer (NSCLC) and the future outlook for patient-specific care.
openaccessgovernment8 天
Personalized medicine in oncology: Small molecule inhibitors, biologics and immunotherapies
Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...
Targeted Oncology1 天
AI Prognostic Tool for NSCLC Earns FDA Breakthrough Designation
The FDA granted breakthrough status to Serial CTRS, an AI tool that improves survival predictions in non–small cell lung ...
openaccessgovernment4 天
New genetic mutation linked to drug resistance in non-small cell lung cancer
A new case report details a novel genetic mutation linked to drug resistance in a non-small cell lung cancer patient ...
中国日报网5 天
Shanghai Henlius Biotech's lung cancer drug gets EU approval
Hong Kong-listed Shanghai Henlius Biotech Inc, a subsidiary of Fosun Pharma, announced on Wednesday that its anti-PD-1 mAb, ...
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in ...
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...